Filtered By:
Drug: SGLT2 Inhibitors
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 230 results found since Jan 2013.
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
Source: American Heart Journal - September 6, 2018 Category: Cardiology Source Type: research
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Publication date: Available online 1 September 2018Source: Indian Heart JournalAuthor(s): A.K. PancholiaAbstractPatients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2)-inhibitors are the new class of glucose lowering medications that increase urin...
Source: Indian Heart Journal - September 1, 2018 Category: Cardiology Source Type: research
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
AbstractIndividuals with diabetes mellitus exhibit an increased propensity to develop cardiovascular disorders such as coronary artery disease, stroke and heart failure. Over recent decades, numerous cardiovascular outcome trials in individuals with type 2 diabetes have been published, with data showing a reduction of cardiovascular morbidity and mortality by sodium –glucose cotransporter 2 (SGLT2) inhibitors. These results not only provide novel therapeutic options for this high-risk population but also advance our current understanding of cardiovascular risk reduction in diabetes. The current overview article summarise...
Source: Diabetologia - August 31, 2018 Category: Endocrinology Source Type: research
Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
AbstractPurpose of ReviewWe review the cardiovascular and renal outcomes and safety of newer anti-diabetic medications in high-risk patients. We examine the outcomes of the IRIS, EMPA-REG OUTCOME, CANVAS, LEADER, SAVOR-TIMI 53, and EXAMINE trials demonstrating the cardiovascular and renal benefits of thiazolidinediones, SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors.Recent FindingsDiabetes mellitus is a leading risk factor for cardiovascular disease with rising prevalence and disease burden. The microvascular and macrovascular complications of diabetes are well-recognized and include increased risk of cardiovascula...
Source: Current Cardiology Reports - June 21, 2018 Category: Cardiology Source Type: research
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2 ‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - April 17, 2018 Category: Endocrinology Authors: Mikhail
Kosiborod
MD
,
K åre I.
Birkeland
MD
,
Matthew A.
Cavender
MD
,
Alex Z.
Fu
PhD
,
John P.
Wilding
MD
,
Kamlesh
Khunti
MD
,
Reinhard W.
Holl
MD
,
Anna
Norhammar
MD
,
Marit E.
Jørgensen
MD
,
Eric T.
Wittbrodt
Ph Source Type: research
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta ‐analysis
Diabetes, Obesity and Metabolism, EarlyView.
Source: Diabetes, Obesity and Metabolism - April 17, 2018 Category: Endocrinology Authors: Man
Guo
MD
,
Jingya
Ding
MD
,
Jingsong
Li
MD
,
Jiying
Wang
MD
,
Ting
Zhang
MD
,
Cuiping
Liu
MD
,
Wei
Huang
MD
,
Yang
Long
PhD
,
Chenlin
Gao
MD
,
Yong
Xu
MD Source Type: research
The kidney and cardiovascular outcome trials
Chronic kidney disease (CKD) affects a substantial minority of people with type 2 diabetes (T2D). Analysis of US National Health and Nutrition Examination Survey (NHANES) datasets from 2007 through 2012 showed Stage 3 or worse disease (estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2) in nearly one in five patients, with increasing age, blood pressure, obesity, and levels of glycemia all associated with higher likelihood of Stage 3 or worse CKD, comparable to findings from surveys from many other areas, which also show micro‐ or macroalbuminuria to be present in one‐sixth to one‐third of diab...
Source: Journal of Diabetes - January 19, 2018 Category: Endocrinology Authors: Zachary Bloomgarden Tags: Editorial Source Type: research
Cardiovascular outcomes with canagliflozin - is it on the CANVAS?
Authors: Doggrell S
Abstract
INTRODUCTION: Sodium-glucose cotransporter 2 (SGLT2) inhibitors (the 'gliflozins') promote the excretion of glucose from the kidney to lower HbA1c. Empagliflozin was the first gliflozin shown to improve cardiovascular and renal outcomes in subjects with type 2 diabetes and cardiovascular disease. Areas covered: In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, there were improvements in the primary cardiovascular and exploratory renal outcomes with canagliflozin, compared to placebo. The safety outcome finding, which was of most interest, was that there was a higher...
Source: Expert Opinion on Pharmacotherapy - December 20, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type2 diabetes mellitus
Persons with type2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a r...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research
SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
Persons with type 2 diabetes mellitus (T2DM) are at higher risk than persons without diabetes of developing atherosclerotic vascular diseases and events including myocardial infarction and stroke, as well as complications such as chronic kidney disease [1,2]. Optimal management of their diabetes and its comorbidities is required to address the increased risk of cardiovascular and related diseases [3]. Certain sodium –glucose co-transporter 2 (SGLT2) inhibitors have recently been shown to improve cardiovascular outcomes in high cardiovascular-risk individuals with T2DM, with empagliflozin being the first to demonstrate a ...
Source: Diabetes Research and Clinical Practice - November 28, 2017 Category: Endocrinology Authors: Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E. Cooper Tags: Review Source Type: research
Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.
Abstract
Resistant hypertension is a multifactorial disease associated with several target organ damage, such as microalbuminuria, left ventricular hypertrophy and arterial stiffness. These subjects have high cardiovascular complications, especially when associated with diabetes condition. SGLT-2 inhibitors represent a new class of oral antidiabetic drugs that have shown positive effects in diabetics and even hypertensives subjects. Several studies demonstrated positive outcomes related to blood pressure levels, body weight and glycemic control. Also found a reduction on microalbuminuria, cardiac and arterial remo...
Source: American Journal of Hypertension - November 23, 2017 Category: Cardiology Authors: Pioli MR, Ritter AMV, Modolo R Tags: Am J Hypertens Source Type: research
Can we go beyond surrogates?
Two years ago, data presented at the annual American Diabetes Association (ADA) meeting in New Orleans showed a marked decrease in deaths, especially those due to cardiovascular disease, with the use of empagliflozin. Two major questions have been asked: (i) was the result a fluke; and (ii) was it a class effect, or was it specific to the agent used? The hope that both questions would be answered by a second study has been answered: the conclusions of EMPA‐REG were not an anomaly and it is a class effect, not one caused by a specific drug. Importantly, do these studies require us to alter our algorithms for the treatment...
Source: Journal of Diabetes - October 19, 2017 Category: Endocrinology Authors: Andrew Drexler Tags: Editorial Source Type: research
The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Abstract
Introduction Sodium-glucose co-transporters-2inhibitors have emerged as a very promising antidiabetic drug class, with data from the two available cardiovascular trials of this class suggesting remarkable benefits in terms of cardiovascular events, total mortality and renal outcomes. Areas covered Data point toward clinically meaningful benefits from SGLT-2inhibition on a variety of cardiovascular risk factors. Empagliflozin, and to a lesser extent canagliflozin, resulted in significant reductions of an abundance of cardiovascular mortality and morbidity endpoints. SGLT-2inhibitors were also found to redu...
Source: Pharmacological Reviews - August 22, 2017 Category: Drugs & Pharmacology Authors: Imprialos KP, Stavropoulos K, Doumas M, Karagiannis A, Athyros VG Tags: Expert Rev Clin Pharmacol Source Type: research
Benefits of SGLT2 Inhibitors beyond glycemic control - A focus on metabolic, cardiovascular, and renal outcomes.
CONCLUSIONS: SGLT2 inhibitors demonstrate some positive metabolic effects. In addition, empagliflozin specifically has demonstrated reduction in cardiovascular events and delay in the progression of kidney disease in patients with T2DM and a history of cardiovascular disease. Further data is needed to assess if this is a class effect.
PMID: 28814245 [PubMed - as supplied by publisher]
Source: Current Diabetes Reviews - August 16, 2017 Category: Endocrinology Authors: Minze MG, Will K, Terrell BT, Black RL, Irons BK Tags: Curr Diabetes Rev Source Type: research
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research
